Adalvo, in partnership with STADA, announces the commercial launch of generic Ivermectin 10mg/g (1%) cream in Germany. It is believed to be the first generic alternative to Soolantra (Galderma) available to patients in Europe.
Ivermectin cream is indicated for the treatment of inflammatory lesions – the pimples and spots associated with rosacea, a condition affecting an estimated 5% of the global population, which can significantly impact quality of life.
Ivermectin cream, with its dual anti-inflammatory and antiparasitic mechanism of action, has become an important option in managing the condition.
The availability of Adalvo’s generic represents a meaningful step towards broader patient access to an established, well-regarded therapy with sustained demand.
Working alongside STADA, one of Europe's leading generics and branded medicines companies, Adalvo has delivered on the Day-1 launch ambition.
“Through our partnership with Adalvo, we are bringing a high-quality, affordable treatment option to patients in Germany, while equipping physicians and pharmacists with a reliable option to support patient care,” commented Basem Yazgi, General Manager of STADA’s ALIUD PHARMA German generics business.
Anil Okay, Adalvo’s CEO, said: “This launch is another great example of the value Adalvo offers our partners: early market entry with a high-quality product that lowers costs for those who are most in need, while helping partners gain a strong foothold.”
Adalvo's dermatology portfolio continues to expand, with Ivermectin cream joining Adapalene + Benzoyl Peroxide Gel, Tacrolimus Ointment, and Apremilast film coated tablets.
To discuss licensing or commercial opportunities within Adalvo's dermatology portfolio, contact the team today.